Cryoport, Inc., a global supply chain solutions provider for the life sciences industry, and SK pharmteco, a global CDMO, entered a strategic collaboration to provide integrated logistics and manufacturing services to biotechnology and pharmaceutical companies.
 
Cryoport will leverage its cell and gene therapy support services from biomaterial collection to final delivery via its integrated supply chain services and equipment, including its shipping systems, data solutions, and bioservices, to support SK pharmteco’s contract manufacturing of both small molecule and cell and gene therapy products.
 
“We are delighted to be selected by SK pharmteco in supporting its manufacture of APIs and intermediates, biopharmaceuticals, and cell and gene therapies,” said Jerrell Shelton, CEO of Cryoport. “Our organizations share a mission to support the life sciences by helping bring lifesaving treatments to patients. This relationship not only extends our reach to more people in need but also aligns with Cryoport’s strategic goal to further diversify and enhance our revenue streams, particularly as we continue to drive higher revenue from the support of commercial cell and gene therapies.”
 
Dana Cipriano, Vice President, Analytical Services for SK pharmteco, added, “The cell and gene therapy industry continues to see substantial growth, and ensuring the safety and integrity of the supply chain is essential for these products. We are dedicated to our clients, and partnering with Cryoport reflects our commitment to providing the highest-quality services that are specifically tailored to meet the needs of our customers and the patients they serve.”